Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 10, Pages 2039-2049
Publisher
Springer Nature
Online
2015-05-15
DOI
10.1038/leu.2015.123
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1
- (2014) M. Mraz et al. BLOOD
- Daratumumab granted breakthrough drug status
- (2014) Jacob P Laubach et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
- (2014) Saskia Meyer et al. mAbs
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
- (2013) Allan Lipton et al. BREAST CANCER RESEARCH AND TREATMENT
- Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
- (2013) S. J. de Haart et al. CLINICAL CANCER RESEARCH
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Cancer's true breakthroughs
- (2013) Elie Dolgin NATURE MEDICINE
- Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL
- (2012) Yuhko Suzuki et al. ANNALS OF HEMATOLOGY
- Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
- (2012) R. W. J. Groen et al. BLOOD
- Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
- (2012) Sambasiva P. Rao et al. PLoS One
- CD38 and chronic lymphocytic leukemia: a decade later
- (2011) F. Malavasi et al. BLOOD
- rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
- (2011) X. Ge et al. CLINICAL CANCER RESEARCH
- Editorial: CD38 and retinoids: a step toward a cure
- (2011) Fabio Malavasi JOURNAL OF LEUKOCYTE BIOLOGY
- All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-δ
- (2011) Akira Uruno et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
- (2010) Allan Lipton et al. CANCER
- Treatment of relapsed and refractory multiple myeloma in the era of novel agents
- (2010) Niels W.C.J. van de Donk et al. CANCER TREATMENT REVIEWS
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells
- (2010) T Vaisitti et al. LEUKEMIA
- An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
- (2009) Y. Mishima et al. CLINICAL CANCER RESEARCH
- Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
- (2008) N. A. Johnson et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started